Vitamins for Chinese Pharma

Science  02 Jun 2006:
Vol. 312, Issue 5778, pp. 1291d
DOI: 10.1126/science.312.5778.1291d

China's burgeoning pharmaceutical industry got a boost last week from U.K.-based AstraZeneca, which announced a 3-year, $100 million research investment. The firm has conducted clinical research in China since 2001 (Science, 29 July 2005, p. 735). Most of the new money will increase efforts to apply basic discoveries to clinical practice, including, by 2009, a so-called Innovation Center at a site to be decided later. The company also plans to expand in-country collaborations, including its partnership with researchers at Shanghai Jiao Tong University on the genetics of schizophrenia.

Related Content

Navigate This Article